Heterocyclic compounds and their preparation and use
申请人:Novo Nordisk A/S
公开号:US05646146A1
公开(公告)日:1997-07-08
The present invention relates to 9H-indeno[1,2-b]pyrazin-3(4H)-ones and 9H-indeno[1,2-b]pyrazine-2,3(1H,4H)-diones or tautomeric forms thereof which are useful in treating neurological and psychiatric diseases based on the antagonism of the glycine binding site on the NMDA receptor complex.